Key Points
- Insider purchase: Leah Neufeld bought 2,626 shares on Jan. 13 at $4.15 each for $10,897.90, raising her stake to 25,970 shares (an 11.25% increase).
- Shares opened at $4.64 (up 4.7%) with a market cap of about $299.6M and negative EPS; analysts show bullish sentiment with an average price target of $16.50 and top targets up to $30.
- Immuneering is an AI-driven clinical-stage biopharma whose lead program, IRX-2, is in Phase 2 trials for painful diabetic peripheral neuropathy.
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Leah Neufeld purchased 2,626 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was bought at an average price of $4.15 per share, with a total value of $10,897.90. Following the completion of the transaction, the insider owned 25,970 shares of the company's stock, valued at $107,775.50. The trade was a 11.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Immuneering Trading Up 4.7%
Shares of IMRX stock opened at $4.64 on Friday. Immuneering Corporation has a twelve month low of $1.10 and a twelve month high of $10.08. The stock has a fifty day simple moving average of $6.41 and a two-hundred day simple moving average of $5.77. The stock has a market capitalization of $299.60 million, a price-to-earnings ratio of -2.61 and a beta of 0.48.
Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Research analysts predict that Immuneering Corporation will post -1.86 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. Hudson Bay Capital Management LP acquired a new stake in shares of Immuneering in the third quarter worth approximately $717,000. CIBC Private Wealth Group LLC lifted its position in Immuneering by 233.7% in the third quarter. CIBC Private Wealth Group LLC now owns 50,051 shares of the company's stock valued at $350,000 after buying an additional 35,051 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Immuneering during the 3rd quarter worth approximately $350,000. Heights Capital Management Inc. acquired a new position in Immuneering during the third quarter worth $140,000. Finally, Woodline Partners LP purchased a new position in Immuneering during the 3rd quarter valued at about $1,050,000. Institutional investors and hedge funds own 67.65% of the company's stock.
Analysts Set New Price Targets
A number of analysts have weighed in on the company. Oppenheimer upped their target price on Immuneering from $21.00 to $30.00 and gave the stock an "outperform" rating in a report on Thursday, September 25th. Leerink Partnrs raised shares of Immuneering to a "strong-buy" rating in a research report on Friday, October 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immuneering in a research note on Monday, December 29th. Mizuho set a $12.00 price target on shares of Immuneering in a report on Wednesday, October 29th. Finally, Chardan Capital restated a "buy" rating and set a $20.00 price target on shares of Immuneering in a research note on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $16.50.
Check Out Our Latest Analysis on Immuneering
About Immuneering
(
Get Free Report)
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
